Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/TRA2B_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/TRA2B_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/TRA2B_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/TRA2B_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/TRA2B_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TRA2B_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/TRA2B_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TRA2B_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/TRA2B_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TRA2B_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/TRA2B_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/TRA2B_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TRA2B_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000037517 | Prostate | BPH | RNA splicing, via transesterification reactions | 114/3107 | 324/18723 | 2.19e-16 | 4.53e-14 | 114 |
GO:000037717 | Prostate | BPH | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 112/3107 | 320/18723 | 6.21e-16 | 1.07e-13 | 112 |
GO:000039817 | Prostate | BPH | mRNA splicing, via spliceosome | 112/3107 | 320/18723 | 6.21e-16 | 1.07e-13 | 112 |
GO:000697918 | Prostate | BPH | response to oxidative stress | 142/3107 | 446/18723 | 8.11e-16 | 1.36e-13 | 142 |
GO:004802418 | Prostate | BPH | regulation of mRNA splicing, via spliceosome | 51/3107 | 101/18723 | 3.74e-15 | 5.26e-13 | 51 |
GO:000030218 | Prostate | BPH | response to reactive oxygen species | 76/3107 | 222/18723 | 9.75e-11 | 5.92e-09 | 76 |
GO:000038010 | Prostate | BPH | alternative mRNA splicing, via spliceosome | 35/3107 | 77/18723 | 2.89e-09 | 1.13e-07 | 35 |
GO:000038110 | Prostate | BPH | regulation of alternative mRNA splicing, via spliceosome | 29/3107 | 60/18723 | 1.16e-08 | 3.81e-07 | 29 |
GO:19033138 | Prostate | BPH | positive regulation of mRNA metabolic process | 41/3107 | 118/18723 | 1.23e-06 | 2.16e-05 | 41 |
GO:003312010 | Prostate | BPH | positive regulation of RNA splicing | 17/3107 | 37/18723 | 2.89e-05 | 3.34e-04 | 17 |
GO:000974318 | Prostate | BPH | response to carbohydrate | 67/3107 | 253/18723 | 4.20e-05 | 4.48e-04 | 67 |
GO:003428418 | Prostate | BPH | response to monosaccharide | 61/3107 | 225/18723 | 4.34e-05 | 4.60e-04 | 61 |
GO:000974617 | Prostate | BPH | response to hexose | 58/3107 | 219/18723 | 1.33e-04 | 1.19e-03 | 58 |
GO:000974915 | Prostate | BPH | response to glucose | 55/3107 | 212/18723 | 3.42e-04 | 2.55e-03 | 55 |
GO:00480268 | Prostate | BPH | positive regulation of mRNA splicing, via spliceosome | 10/3107 | 22/18723 | 1.46e-03 | 8.65e-03 | 10 |
GO:000167810 | Prostate | BPH | cellular glucose homeostasis | 44/3107 | 172/18723 | 1.71e-03 | 9.87e-03 | 44 |
GO:007133310 | Prostate | BPH | cellular response to glucose stimulus | 39/3107 | 151/18723 | 2.52e-03 | 1.35e-02 | 39 |
GO:007133110 | Prostate | BPH | cellular response to hexose stimulus | 39/3107 | 153/18723 | 3.24e-03 | 1.68e-02 | 39 |
GO:007132215 | Prostate | BPH | cellular response to carbohydrate stimulus | 41/3107 | 163/18723 | 3.35e-03 | 1.73e-02 | 41 |
GO:007132610 | Prostate | BPH | cellular response to monosaccharide stimulus | 39/3107 | 154/18723 | 3.65e-03 | 1.85e-02 | 39 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TRA2B | SNV | Missense_Mutation | | c.62G>A | p.Gly21Glu | p.G21E | P62995 | protein_coding | deleterious_low_confidence(0.04) | benign(0.134) | TCGA-A2-A0YM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TRA2B | SNV | Missense_Mutation | rs758758553 | c.221N>A | p.Arg74His | p.R74H | P62995 | protein_coding | tolerated_low_confidence(0.27) | benign(0.375) | TCGA-AR-A254-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
TRA2B | SNV | Missense_Mutation | | c.544A>T | p.Met182Leu | p.M182L | P62995 | protein_coding | tolerated(0.16) | benign(0.079) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TRA2B | SNV | Missense_Mutation | | c.186A>C | p.Arg62Ser | p.R62S | P62995 | protein_coding | tolerated_low_confidence(0.2) | benign(0.012) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TRA2B | SNV | Missense_Mutation | novel | c.734N>C | p.Gly245Ala | p.G245A | P62995 | protein_coding | tolerated_low_confidence(0.07) | possibly_damaging(0.794) | TCGA-XX-A89A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TRA2B | deletion | Frame_Shift_Del | novel | c.821delN | p.Tyr274SerfsTer18 | p.Y274Sfs*18 | P62995 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
TRA2B | SNV | Missense_Mutation | novel | c.772N>G | p.Gln258Glu | p.Q258E | P62995 | protein_coding | tolerated_low_confidence(0.22) | benign(0.042) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TRA2B | SNV | Missense_Mutation | | c.275N>A | p.Arg92Lys | p.R92K | P62995 | protein_coding | deleterious(0.04) | possibly_damaging(0.745) | TCGA-EK-A2RN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TRA2B | SNV | Missense_Mutation | novel | c.650N>T | p.Arg217Leu | p.R217L | P62995 | protein_coding | deleterious(0.01) | benign(0.003) | TCGA-JX-A5QV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TRA2B | SNV | Missense_Mutation | novel | c.296N>G | p.Ser99Cys | p.S99C | P62995 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-MY-A5BF-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |